Pfizer (NYSE:PFE) released detailed Phase 2b results for berobenatide, its investigational monthly GLP-1 receptor agonist for obesity. The data show proof of concept with favorable tolerability and low reported adverse events in the trial setting. Pfizer has started Phase 3 trials and outlined a broader clinical program for berobenatide as part of its late-stage obesity pipeline. For investors tracking NYSE:PFE, this update offers a clearer view of how Pfizer is positioning itself in the...